Abbreviations
In this guide
In this guide|
ASA |
Advertising Standards Authority |
|
AUC0-n |
Integrated area under the time-concentration curve following administration of a compound from 0 to n hours. |
|
BCM-95 |
Curcumin formulation composed of 95% standardised curcuminoids and turmeric essential oils. |
|
BDMC |
Bisdemethoxycurcumin |
|
BMI |
Body mass index |
|
CBD |
Cannabidiol |
|
Cmax |
Highest plasma concentration achieved following administration of a compound. |
|
COT |
The Committee on Toxicity of Chemicals in Food, Consumer Products, and the Environment |
|
DAGs |
Diacylglycerols |
|
DMC |
Demethoxycurcumin |
|
FFA |
Free fatty acids |
|
GIT |
Gastrointestinal tract |
|
GRAS |
Generally recognised as safe. |
|
HBGV |
Health-based guidance value |
|
LCFA |
Long chain fatty acids |
|
MAGs |
Monoacylglycerols |
|
MCT |
Medium chain triglycerides |
|
MTHF |
Methyltetrahydrofolate |
|
NAD+ |
Nicotinamide adenine dinucleotide |
|
NIH |
National Institutes of Health |
|
NLC |
Nanostructured lipid carriers |
|
NMN |
Nicotinamide mononucleotide |
|
PDI – |
Polydispersity index |
|
SE(M/N)DDS |
Self-emulsifying (micro/nano) drug delivery system |
|
SLCP |
Solid lipid curcumin particles |
|
SLN |
Solid lipid nanoparticles |
|
THC |
Tetrahydrocurcumin (c.f. the cannabinoid tetrahydrocannabinol ‘THC’, is not discussed in this paper) |
|
Tmax |
Timepoint following administration of a compound at which highest plasma concentration is achieved. |